Dorothy Hitchmoth, OD
Optometrist · New London, NHNPI 1043270796
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $183,803 of the $224,601 with a category attached, or 81.8%. Carl Zeiss Meditec, Inc. accounts for 88.2% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2019 at $116,803 and has fallen 98.0% since, to $2,355 in 2025. Among optometrist clinicians in NH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 158 payments — averaging $1421.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Carl Zeiss Meditec, Inc.$198K
- LKC Technologies, Inc.$10K
- Sun Pharmaceutical Industries Inc.$7K
- Tarsus Pharmaceuticals, Inc.$2K
- Ocular Therapeutix, Inc.$1K
- Regeneron$1K
- plus $5K from 16 others
What the payments were for
- Consulting fees$183,80382%
- Speaking & faculty fees$17,1758%
- Travel & lodging$16,0247%
- Food & beverage$6,3373%
- Education$1,2451%
- Gifts$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Carl Zeiss Meditec, Inc. | 94 | $198,044 |
| LKC Technologies, Inc. | 3 | $10,073 |
| Sun Pharmaceutical Industries Inc. | 8 | $6,924 |
| Tarsus Pharmaceuticals, Inc. | 9 | $1,512 |
| Ocular Therapeutix, Inc. | 2 | $1,458 |
| Regeneron | 1 | $1,225 |
| Carl Zeiss Meditec USA, Inc. | 10 | $1,103 |
| Seagen Inc. | 1 | $990 |
| AbbVie(2 entities) | 6 | $541 |
| Apellis Pharmaceuticals, Inc. | 1 | $500 |
| Heru, Inc. | 1 | $500 |
| Dompe US, Inc. | 4 | $345 |
| Coopervision Inc. | 3 | $285 |
| Novartis | 5 | $226 |
| Johnson & Johnson Vision Care, Inc. | 1 | $193 |
| Oyster Point Pharma, Inc. | 2 | $191 |
| Alcon | 2 | $170 |
| Glaukos Corporation | 1 | $146 |
| Samsara Vision | 1 | $57 |
| Lombart Brothers, Inc. | 1 | $49 |
| Kala Pharmaceuticals, Inc. | 1 | $35 |
| Shire North American Group Inc | 1 | $33 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CLARUS 500 Fundus Camera$50,726
- CIRRUS HD-OCT$43,896
- FORUM$40,163
- CLARUS$9,100
- CEQUA$6,861
- Humphrey HFA$2,290
- IOLMaster$1,750
- DEXTENZA$1,400
- EYLEA$1,225
- TIVDAK$990
- Syfovre$500
- Heru HMD$500
- CLARUS 500$379
- XDEMVY$265
- MyDay Contact Lens$234
- Oxervate$212
- Acuvue$193
- CIRRUS 5000 with AngioPlex$175
- RADIUS$146
- LUMIGAN$145
How this compares
$224,601 in reported general payments places this provider in the 95th percentile of 235 optometrist providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 18 | $24,947 |
| MieboPerfluorohexyloctane/Pf | 15 | $21,373 |
| Cyclosporine | 15 | $10,063 |
| CombiganBrimonidine Tartrate/Timolol | 14 | $7,468 |
| LumiganBimatoprost | 18 | $6,316 |
| Brimonidine Tartrate | 24 | $3,389 |
| Latanoprost | 227 | $2,551 |
| Prednisolone Acetate | 49 | $2,089 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 41 | $617 |
| Timolol Maleate | 34 | $341 |
| ErythromycinErythromycin Base | 20 | $289 |
| ValacyclovirValacyclovir Hcl | 16 | $268 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Combigan, Lumigan | $541 | $38,73150 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 235 optometrist providers in New Hampshire.
Other optometrist in New London
- Lauren McLoughlinPortsmouth$138K
- Debra Poulin-BelairBarrington$55K
- Kelly MacdonaldNashua$6K
- Sarah HudsonPortsmouth$6K
- Sarah WoodDerry$5K
- Renee LynchPortsmouth$5K
- Rinita TrahanPortsmouth$5K
- Jill FedericoPortsmouth$5K
- Karl EngelhartConcord$4K
- Amy Catalano BoyerGreenland$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.